InMed Pharmaceuticals (INM) EPS (Basic) (QoQ) (2021 - 2026)
InMed Pharmaceuticals (INM) EPS (Basic) (QoQ) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - |
| 10 | InMed Pharmaceuticals | 6.38 Mn | 1.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 91.59% |
| Dec 31, 2025 | -17.45% |
| Sep 30, 2025 | 67.38% |
| Jun 30, 2025 | -2,623.78% |
| Mar 31, 2025 | 98.65% |
| Dec 31, 2024 | -34.70% |
| Sep 30, 2024 | 46.60% |
| Jun 30, 2024 | -41.34% |
| Mar 31, 2024 | 3.33% |
| Dec 31, 2023 | 75.68% |
| Sep 30, 2023 | -454.46% |
| Jun 30, 2023 | 77.08% |
| Mar 31, 2023 | 34.23% |
| Dec 31, 2022 | 77.51% |
| Sep 30, 2022 | 71.10% |
| Jun 30, 2022 | -128.55% |
| Mar 31, 2022 | 20.59% |
| Dec 31, 2021 | -25.39% |